Kronos parlays diverse pipeline into $105M series A

The speed at which Kronos assembled a broad small molecule platform against hard-to-target hormone receptors, transcription factors and E3 ligases enabled it to raise a $105 million A round led by seed investors Vida Ventures and Omega Funds -- more than twice the amount the company originally sought.

President and CEO Norbert Bischofberger told BioCentury the round will give Kronos Bio Inc. (San Mateo, Calif.) runway for at least two years, during which it plans to bring two compounds into the clinic and continue advancing its preclinical pipeline, including a tissue-agnostic candidate and a newly unveiled protein degradation program...